Earnings summaries and quarterly performance for AVANOS MEDICAL.
Executive leadership at AVANOS MEDICAL.
David Pacitti
Detailed
Chief Executive Officer
CEO
Kerr W. Holbrook
Detailed
Senior Vice President and Chief Commercial Officer
Mojirade A. James
Detailed
Senior Vice President, General Counsel and Secretary
Scott Galovan
Detailed
Senior Vice President, Chief Financial Officer
Sigfrido Delgado
Detailed
Senior Vice President, Operations
Board of directors at AVANOS MEDICAL.
Research analysts who have asked questions during AVANOS MEDICAL earnings calls.
Daniel Stauder
Citizen JMP
3 questions for AVNS
Also covers: AORT, ATRC, LMAT +2 more
Anton Gvozdikov
Stifel
1 question for AVNS
Danis
Citizens CM
1 question for AVNS
Frederick Wise
Stifel
1 question for AVNS
Also covers: AORT, ATRC, BDX +13 more
Kristen Stewart
CL King & Associates
1 question for AVNS
Also covers: CNMD, HAE, IART +3 more
Recent press releases and 8-K filings for AVNS.
Avanos Reports Q3 2025 Results and Updates 2025 Guidance
AVNS
Earnings
Guidance Update
M&A
- Avanos reported net sales of $178 million and adjusted diluted earnings per share of $0.22 for the third quarter of 2025.
- The company raised and narrowed its full-year 2025 revenue estimate to $690-$700 million and its adjusted EPS estimate to $0.85-$0.95 per share.
- Strategic actions included the divestiture of the hyaluronic acid business on July 31 and the acquisition of Nexus Medical, which is expected to be immediately accretive to both revenue growth and earnings per share.
- Avanos expects to achieve $15-$20 million of run-rate annualized incremental cost savings by the end of 2026, with $10 million in one-time cash charges anticipated in the fourth quarter of 2025.
- The estimated P&L impact of incremental tariff-related manufacturing costs for 2025 is approximately $18 million, and the company anticipates generating $25-$30 million of free cash flow for the year.
Nov 5, 2025, 2:00 PM
Avanos Medical Updates Full-Year 2025 Guidance and Reports Q3 2025 Results
AVNS
Guidance Update
Earnings
M&A
- Avanos Medical raised and narrowed its full-year 2025 guidance, with Net Sales now estimated between $690 million and $700 million and Adjusted EPS between $0.85 and $0.95 per share.
- For Q3 2025, the company reported Net Sales of $178 million and Adjusted EPS of $0.22.
- The combined strategic segments, Specialty Nutrition Systems and Pain Management & Recovery, achieved 10% organic growth. Specialty Nutrition Systems Net Sales grew to $114 million in Q3 2025.
- Avanos deployed capital into the acquisition of Nexus Medical and optimized its product portfolio with the sale of its Hyaluronic Acid product line. The company also expanded transformation initiatives to deliver $15 to $20 million of incremental annualized savings by the end of 2026.
Nov 5, 2025, 2:00 PM
Avanos Medical, Inc. Announces Q3 2025 Results, Raises Full-Year Guidance, and Details Strategic Transactions
AVNS
Earnings
Guidance Update
M&A
- Avanos Medical reported net sales of $177.8 million for Q3 2025, a 4.3% increase from the prior year, alongside a net loss of $1.4 million and diluted loss per share of $0.03.
- Adjusted diluted earnings per share for Q3 2025 was $0.22, compared to $0.36 a year ago, and adjusted EBITDA was $20.2 million.
- The company completed the acquisition of Nexus Medical and divested its HA product line during the quarter.
- Avanos Medical raised and narrowed its full-year 2025 guidance, with estimated revenue now projected between $690 million and $700 million and adjusted diluted earnings per share between $0.85 and $0.95.
Nov 5, 2025, 12:01 PM
Avanos Medical, Inc. Announces Third Quarter 2025 Results and Updates Full-Year Guidance
AVNS
Earnings
Guidance Update
M&A
- Avanos Medical reported third quarter 2025 net sales of $177.8 million, a 4.3% increase from the comparable prior year period, but recorded a net loss of $1.4 million and diluted loss per share of $0.03.
- The Specialty Nutrition Systems (SNS) segment achieved net sales of $114.0 million in Q3 2025, driven by 14.0% volume growth.
- For the nine months ended September 30, 2025, the company reported an operating loss of $64.1 million, which included a $77.0 million goodwill impairment charge in the second quarter within the Pain Management & Recovery (PM&R) segment.
- Avanos completed the acquisition of Nexus Medical and divested its HA product line on July 31, 2025, as part of its strategic transformation.
- The company raised and narrowed its 2025 estimated revenue guidance to between $690 million and $700 million and its adjusted diluted earnings per share guidance to a new range of $0.85 to $0.95.
Nov 5, 2025, 12:00 PM
Avanos Medical Reports Q2 2025 Results, Announces Divestiture and Leadership Changes
AVNS
Earnings
CFO Change
M&A
- Avanos Medical reported Q2 2025 net sales of $175.0 million, a 1.9% increase year-over-year, but a net loss of $76.8 million and diluted loss per share of $1.66, largely due to a $77.0 million goodwill impairment charge.
- The company announced the divestiture of its Hyaluronic Acid (HA) product line to Channel-Markers Medical, LLC on July 31, 2025, aligning with its strategy to focus on Pain Management & Recovery and Specialty Nutrition Systems.
- Scott Galovan was appointed Senior Vice President, Chief Financial Officer, effective August 1, 2025, and CEO David Pacitti was appointed to the Board of Directors on the same date.
- Avanos Medical maintained its 2025 estimated revenue guidance of $665 million to $685 million and adjusted diluted earnings per share guidance of $0.75 to $0.95.
Aug 5, 2025, 12:00 AM
Avanos Divests Hyaluronic Acid Product Line
AVNS
M&A
- Avanos Medical, Inc. has divested its Hyaluronic Acid (HA) product line, which includes the TriVisc® and GenVisc® 850 injection products, to Channel-Markers Medical, LLC (CMM).
- This transaction aligns with Avanos' ongoing transformation strategy, aimed at advancing its strategic segments in Pain Management & Recovery and Specialty Nutrition Systems.
- Ownership of the HA product line officially transferred to CMM on July 31, 2025, with Avanos providing transition support through the end of 2025.
Jul 31, 2025, 8:15 PM
Avanos Medical Inc Q1 2025 Results & CEO Update
AVNS
Earnings
CEO Change
Guidance Update
- Financial Performance: Delivered strong Q1 2025 results with net sales of $168 million, net income of $6.6 million, and operating income of $10.3 million (adjusted to $17.1 million), alongside 18% adjusted EPS growth .
- CEO & Leadership Change: New CEO David Pacitti and Interim CFO Jason Pickett were introduced to drive transformational initiatives and enhanced cost controls .
- Guidance & Tariff Impact: Revised full-year guidance with adjusted diluted EPS forecast of $0.75–$0.95 and revenue guidance of $665M–$685M amid an incremental tariff impact of $15 million .
- Segment Performance: Specialty Nutrition Systems grew nearly 9% organically while the Pain Management segment showed significant operational improvements, with an additional 0.8% net sales increase reported .
- Free Cash Flow: Generated $19 million in Q1 free cash flow and forecasted full-year free cash flow of $65 million (excluding tariff effects) .
May 6, 2025, 1:01 PM
Avanos Medical 2025 Annual Meeting and Proxy Vote Outcomes
AVNS
Proxy Vote Outcomes
Auditor Change
Board Change
- Stockholders’ Annual Meeting held on April 24, 2025 at the Company’s headquarters in Alpharetta, Georgia, with 43,080,796 shares (93.64% of outstanding voting shares) represented.
- Proxy vote results approved key proposals including the election of directors, the appointment of Deloitte & Touche LLP as independent auditor for 2025, and an amendment to the 2021 Long Term Incentive Plan.
- The filing also includes the required exhibits for the report, notably the Cover Page Interactive Data File.
Apr 25, 2025, 12:00 AM
Avanos Medical Announces Management Changes and Severance Details
AVNS
Management Change
Executive Compensation
- Warren Machan’s role change: The Company amended its Consulting Agreement effective April 14, 2025, transitioning Machan from Interim CFO to a consultant role, with his engagement set to terminate on April 30, 2025 and compensation of $60,000 per month while waiving his Second Bonus.
- Michael Greiner’s departure: On April 18, 2025, Greiner announced his exit as Interim CEO after not being offered a comparable role, triggering a severance package of $2,100,000, prorated bonus, 6-month COBRA premium coverage, and a $50,000 consulting fee during his one-month consultancy, along with immediate vesting of his special equity awards.
Apr 18, 2025, 12:00 AM
Avanos Medical Appoints New CEO David Pacitti
AVNS
CEO Change
Management Change
- David Pacitti has been named chief executive officer for Avanos Medical, effective April 14, 2025.
- Pacitti brings extensive leadership experience from roles at Siemens Healthineers and Abbott Vascular, which positions him to drive strategic growth at Avanos.
Mar 17, 2025, 11:30 AM
Quarterly earnings call transcripts for AVANOS MEDICAL.